A study of the expression of p53 in posttransfection cells with rAdp53 gene and inhibitory activity in vitro

Abstract

Objective To investigate the inhibitory effect and IC 50 (50% inhibiting concentration) of the recombinant adenoviral p53 gene (rAdp53) in colorectal cancer cells in vitro and to guide clinical practice. Methods We evaluated the efficiency (IC 50) of the rAdp53 and six kinds of anti-cancer drugs(5-fluorouracil, tegafur, mitomycin c, cisplatin, oxaliplatin, paclitaxel) in human colorectal cancer cell line-174 through the cell culture and MTT chemosensitivity assay to make sure the anti-cancer capability of rAdp53. Expression of p53 protein in transfection cells of colorectal cancer line-174 with rAdp53 was evaluated by immunohistochemical staining. Results The rAdp53 is a dose and time-dependent anti-cancer drug, its IC 50 is 5.73×10 11 VP/ml, but its effect was not obvious when compared with other anti-cancer drugs. In control group, the immunohistochemistry stain was negative. However, rAd-p53 of five different concentrations were all positive in infected colorectal cancer cells with rAd-p53 and the earliest positive result would present 24 hours after infection. Conclusion The rAdp53 has good anti-cancer efficacy is colorectal cancer cell line-174 in vitro. But its anti-cancer efficacy was less than those of the classical chemical medicine mitomycin c, 5-fluorouracil and cisplatin etc., when it was used alone.